Therapy Areas: Devices
NovaBay Pharmaceuticals Launches Online Sales of CelleRx Skin Cleanser for Post-Aesthetic Dermatology and Cosmetic Surgery Procedures
5 November 2019 - - US-based biopharmaceutical company NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) has launched full-strength CelleRx for consumer purchase without a prescription in the US at, the company said.
CelleRx is a skin and wound cleanser based on NovaBay's proprietary pure hypochlorous formulation, and is proven to gently clean and ease discomfort following aesthetic dermatology and cosmetic surgery procedures.
CelleRx is based on Neutrox, the same pure hypochlorous acid formulation as NovaBay's flagship product Avenova, which is proven to treat the underlying cause of blepharitis and bacterial dry eye. CelleRx has been cleared as a medical device by the US FDA and has CE Marking in the EU.
Hypochlorous acid is a natural agent produced by white blood cells as a function of the innate immune system.
In solution, hypochlorous acid kills both gram-negative and gram-positive bacteria, as well as fungi and biofilms within seconds.
CelleRx is well tolerated and in vitro studies show it quickly neutralizes super antigens (toxins) and pro-inflammatory cytokines without interfering with the growth of underlying new tissue.
Safe and effective, CelleRx is non-irritating, reduces redness and swelling, doesn't dry or stain skin when applied and does not generate antibiotic resistance.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the Neutrox family of products and the Aganocide compounds.
The Neutrox family of products includes Avenova for the eye care market, Neutrophase for wound care market, and Cellrx for the aesthetic dermatology market.
The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.